Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.
Martin C RunnstromPedro A LamotheCaterina E FalitiNarayanaiah CheedarlaAlberto MorenoMehul S SutharRishika NahataMayuran RavindranNatalie S HaddadAndrea Morrison-PorterHannah QuehlRichard P RamonellMatthew WoodruffFabliha AnamRebeca ZhangColin SwensonCarmen PolitoWendy NeveuRahulkumar PatelNatalia SmirnovaDoan C NguyenCaroline KimIan HentenaarShuya KyuSabeena UsmanThuy NgoZhenxing GuoHao WuJohn L DaissJiwon ParkKelly E ManningBursha WaliMadison L EllisSunita SharmaFernando HolguinSuneethamma CheedarlaAndrew S NeishJohn D RobackIgnacio SanzF Eun-Hyung LeePublished in: The Journal of allergy and clinical immunology (2024)
The patients in the PoB group had reduced SARS-CoV-2-specific antibody titers, neutralizing activity, and virus-specific B- and CD8 T-cell counts. These results have implications when considering development of a more individualized immunization strategy in patients who receive biologic medications blocking IL-4 or IL-5 pathways.